Patents under Section 3(j), gene-sequence claims, regulatory data protection, biological resource compliance — Indian biotech sits at one of the most contested IP intersections in the country.
Indian biotech operates under one of the most distinctive IP regimes in the world. Section 3(j) of the Patents Act, 1970 excludes 'plants and animals in whole or any part thereof other than micro-organisms, but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals' from patentability. The Plant Varieties Act, 2001 provides a separate registration regime for new plant varieties. The Biological Diversity Act, 2002 imposes access and benefit-sharing obligations on the use of Indian biological resources. The Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019 layer on regulatory data protection.
For Indian biotech companies — from agricultural biotech to therapeutic biologics to industrial enzymes to gene-editing platforms — navigating these overlapping regimes is the structural challenge. The IP file decides what can be protected as a patent, what falls within PPV&FR registration, what triggers Biological Diversity Act compliance, and what the regulatory data-protection schedule looks like for the eventual product.
Three filings cover most of the IP risk on day one. Each is a standalone service and each links to a deeper walkthrough.
Section 3(j) excludes several specific categories:
The exclusion shapes Indian biotech strategy. Plant variety improvements file under PPV&FR; transgenic plant patents face Section 3(j); microbial inventions remain patentable. Therapeutic biologics — produced by genetically modified cells — typically claim the cell line and the production process rather than the plant or animal source.
The Protection of Plant Varieties and Farmers' Rights Act, 2001 provides a separate registration regime distinct from patents. New plant varieties — extant, farmers', essentially derived — can be registered with the PPV&FR Authority. Registration grants the breeder exclusive rights to produce, sell, market, distribute, import or export the variety for a fixed period (typically 15 years for crops, 18 for trees and vines).
The PPV&FR regime is the Indian counterpart to UPOV-style breeder rights. It accommodates farmers' rights — saving, using, sowing, re-sowing, exchanging, sharing or selling seed without infringement — that are distinctively broad compared with international plant-breeder regimes.
The Biological Diversity Act, 2002 imposes a permit and benefit-sharing regime on the use of Indian biological resources for research, commercial utilisation or intellectual property protection. Indian biotech companies using Indian biological resources — plant, animal or microbial — must:
Failure to comply is criminal under Section 55. The NBA has prosecuted high-profile non-compliance cases. The implication for Indian biotech: source disclosure and NBA approval are part of the IP file, not separate compliance items.
India has no formal data exclusivity regime for pharmaceuticals or biologics. Generic and biosimilar manufacturers can rely on the originator's regulatory data for their own approvals (subject to bioequivalence and biosimilarity studies). The IP protection for biologics, therefore, rests heavily on patents and trade secrets rather than regulatory exclusivity.
Trade secrets in biologics — cell lines, fermentation protocols, purification processes — are protected through contract and confidentiality. Indian biotech contracts typically include detailed trade-secret schedules and assignment clauses to capture process know-how that cannot be easily patented.
The Indian biosimilar regulatory pathway (Guidelines on Similar Biologics, 2016) defines a structured approval route requiring comparative analytical, preclinical and clinical data against the reference biologic. The pathway has produced one of the largest biosimilar pipelines globally; Indian biotech companies have launched biosimilars of major originator biologics including filgrastim, rituximab, trastuzumab and adalimumab.
Indian biotech sits at the patent + PPV&FR + Biological Diversity intersection. Send us the platform spec — we'll map which protections apply and what compliance triggers.
WhatsApp our team →Plants and animals in whole or part (including seeds, varieties, species), and essentially biological processes for production or propagation. The exception: micro-organisms are patentable. Transgenic plants face the exclusion; recombinant microbial inventions remain patentable.
Plant varieties are not patentable under Section 3(j). The Protection of Plant Varieties and Farmers' Rights Act, 2001 provides a separate registration regime granting breeder rights for 15-18 years, accommodating broad farmers' rights to save, exchange and sell seed. PPV&FR is the route for new Indian plant varieties.
Yes. The 2002 Act requires approval from the National Biodiversity Authority for access to Indian biological resources used in research or commercial utilisation, including for IP protection. Source disclosure in patent applications is mandatory. Non-compliance is criminal under Section 55.
No. India does not have a formal data exclusivity regime. Regulatory protection for biologics relies on patents and trade secrets rather than data exclusivity. Biosimilars can be approved on comparative data against the originator without exclusivity-period delays.